Regulus Therapeutics’ (RGLS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a report released on Friday morning,Benzinga reports. HC Wainwright currently has a $10.00 price target on the biopharmaceutical company’s stock.

Regulus Therapeutics Stock Performance

RGLS opened at $1.48 on Friday. Regulus Therapeutics has a 1 year low of $0.83 and a 1 year high of $3.00. The firm has a 50 day moving average price of $1.28 and a 200 day moving average price of $1.46. The company has a market cap of $96.94 million, a PE ratio of -1.38 and a beta of 1.41.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.20). During the same quarter last year, the business posted ($0.40) earnings per share. On average, sell-side analysts predict that Regulus Therapeutics will post -0.88 earnings per share for the current year.

Insider Transactions at Regulus Therapeutics

In related news, VP Christopher Ray Aker sold 38,547 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,569.22. Following the transaction, the vice president now directly owns 54,634 shares of the company’s stock, valued at approximately $68,838.84. The trade was a 41.37 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Preston Klassen sold 31,445 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $39,620.70. Following the completion of the sale, the insider now directly owns 36,055 shares of the company’s stock, valued at $45,429.30. This trade represents a 46.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 223,998 shares of company stock valued at $282,237 over the last quarter. Company insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On Regulus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in shares of Regulus Therapeutics during the third quarter worth about $46,000. PEAK6 LLC purchased a new stake in Regulus Therapeutics during the 4th quarter worth approximately $95,000. Velan Capital Investment Management LP acquired a new position in shares of Regulus Therapeutics in the 4th quarter valued at approximately $111,000. JPMorgan Chase & Co. boosted its stake in shares of Regulus Therapeutics by 193.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 52,059 shares during the last quarter. Finally, Barclays PLC grew its position in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 62,549 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.